A number of studies have documented the safety, efficacy, and cost-effectiveness of outpatient intravenous (iv) antibiotic therapy for patients with infectious diseases.
Nevertheless, Medicare policy prohibiting coverage of outpatient, self-administered drugs has severely limited access of Medicare patients to ambulatory iv therapy, thus forcing them to rely on more costly, inpatient hospital care.
To test the hypothesis that a new Medicare benefit providing coverage for ambulatory iv antibiotic therapy could significantly reduce the program's expenditures for the treatment of infectious diseases (including pneumonia, osteomyelitis, cellulitis, and endocarditis), a cost model was constructed with use of patient care information from the clinical literature as well as clinical experts, Medicare data, and other medical claims databases.
The model shows cumulative 5-year savings of nearly $1.5 billion associated with the new Medicare benefit.
Policy makers should consider implementing such a benefit.
Mots-clés Pascal : Assurance maladie, Couverture, Risque, Chimiothérapie, Ambulatoire, A domicile, Voie intraveineuse, Antibactérien, Antibiotique, Traitement, Modélisation, Analyse avantage coût, Soin, Dépense, Santé, Etats Unis, Amérique du Nord, Amérique, Economie santé
Mots-clés Pascal anglais : Health insurance, Coverage, Risk, Chemotherapy, Ambulatory, At home, Intravenous administration, Antibacterial agent, Antibiotic, Treatment, Modeling, Cost benefit analysis, Care, Expenditure, Health, United States, North America, America, Health economy
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0047212
Code Inist : 002B30A01B. Création : 31/05/1999.